BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31588710)

  • 1. Novel small molecule protein kinase CK2 inhibitors exert potent antitumor effects on T98G and SEGA cells in vitro.
    Pucko E; Ostrowski R; Matyja E
    Folia Neuropathol; 2019; 57(3):239-248. PubMed ID: 31588710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and mechanism of anti-tumor action of new potential CK2 inhibitors toward glioblastoma cells.
    Kaminska B; Ellert-Miklaszewska A; Oberbek A; Wisniewski P; Kaza B; Makowska M; Bretner M; Kazimierczuk Z
    Int J Oncol; 2009 Nov; 35(5):1091-100. PubMed ID: 19787263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent Antitumour Effects of Novel Pentabromobenzylisothioureas Studied on Human Glial-derived Tumour Cell Lines.
    Pucko E; Matyja E; Koronkiewicz M; Ostrowski RP; Kazimierczuk Z
    Anticancer Res; 2018 May; 38(5):2691-2705. PubMed ID: 29715089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The selectivity of inhibitors of protein kinase CK2: an update.
    Pagano MA; Bain J; Kazimierczuk Z; Sarno S; Ruzzene M; Di Maira G; Elliott M; Orzeszko A; Cozza G; Meggio F; Pinna LA
    Biochem J; 2008 Nov; 415(3):353-65. PubMed ID: 18588507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DMAT, an inhibitor of protein kinase CK2 induces reactive oxygen species and DNA double strand breaks.
    Schneider CC; Hessenauer A; Götz C; Montenarh M
    Oncol Rep; 2009 Jun; 21(6):1593-7. PubMed ID: 19424641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and exploitation of CK2 inhibitors.
    Sarno S; Ruzzene M; Frascella P; Pagano MA; Meggio F; Zambon A; Mazzorana M; Di Maira G; Lucchini V; Pinna LA
    Mol Cell Biochem; 2005 Jun; 274(1-2):69-76. PubMed ID: 16335530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2.
    Pagano MA; Meggio F; Ruzzene M; Andrzejewska M; Kazimierczuk Z; Pinna LA
    Biochem Biophys Res Commun; 2004 Sep; 321(4):1040-4. PubMed ID: 15358133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An unbiased evaluation of CK2 inhibitors by chemoproteomics: characterization of inhibitor effects on CK2 and identification of novel inhibitor targets.
    Duncan JS; Gyenis L; Lenehan J; Bretner M; Graves LM; Haystead TA; Litchfield DW
    Mol Cell Proteomics; 2008 Jun; 7(6):1077-88. PubMed ID: 18258654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quinone reductase 2 is an adventitious target of protein kinase CK2 inhibitors TBBz (TBI) and DMAT.
    Leung KK; Shilton BH
    Biochemistry; 2015 Jan; 54(1):47-59. PubMed ID: 25379648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, in vitro antiproliferative activity and kinase profile of new benzimidazole and benzotriazole derivatives.
    Chojnacki K; Wińska P; Skierka K; Wielechowska M; Bretner M
    Bioorg Chem; 2017 Jun; 72():1-10. PubMed ID: 28340404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT.
    Sass G; Klinger N; Sirma H; Hashemolhosseini S; Hellerbrand C; Neureiter D; Wege H; Ocker M; Tiegs G
    Int J Oncol; 2011 Aug; 39(2):433-42. PubMed ID: 21567083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic anti-leukemic effects of CK2 inhibitors and pentabromobenzylisothioureas in vitro.
    Koronkiewicz M; Chilmonczyk Z; Kazimierczuk Z
    Anticancer Res; 2013 Nov; 33(11):4891-9. PubMed ID: 24222126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2.
    Cozza G; Mazzorana M; Papinutto E; Bain J; Elliott M; di Maira G; Gianoncelli A; Pagano MA; Sarno S; Ruzzene M; Battistutta R; Meggio F; Moro S; Zagotto G; Pinna LA
    Biochem J; 2009 Jul; 421(3):387-95. PubMed ID: 19432557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-neoplastic effect of protein kinase CK2 inhibitor, 2-dimethylamino-4,5,6,7-tetrabromobenzimidazole (DMAT), on growth and hormonal activity of human adrenocortical carcinoma cell line (H295R) in vitro.
    Lawnicka H; Kowalewicz-Kulbat M; Sicinska P; Kazimierczuk Z; Grieb P; Stepien H
    Cell Tissue Res; 2010 May; 340(2):371-9. PubMed ID: 20383646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selectivity analysis of protein kinase CK2 inhibitors DMAT, TBB and resorufin in cisplatin-induced stress responses.
    Fritz G; Issinger OG; Olsen BB
    Int J Oncol; 2009 Nov; 35(5):1151-7. PubMed ID: 19787270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multitarget Anticancer Agents Based on Histone Deacetylase and Protein Kinase CK2 inhibitors.
    Martínez R; Geronimo BD; Pastor M; Zapico JM; Coderch C; Panchuk R; Skorokhyd N; Maslyk M; Ramos A; de Pascual-Teresa B
    Molecules; 2020 Mar; 25(7):. PubMed ID: 32218358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFα)-induced apoptosis through SIRT1 inhibition.
    Dixit D; Sharma V; Ghosh S; Mehta VS; Sen E
    Cell Death Dis; 2012 Feb; 3(2):e271. PubMed ID: 22318540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New inhibitors of protein kinase CK2, analogues of benzimidazole and benzotriazole.
    Bretner M; Najda-Bernatowicz A; Łebska M; Muszyńska G; Kilanowicz A; Sapota A
    Mol Cell Biochem; 2008 Sep; 316(1-2):87-9. PubMed ID: 18548199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CK2 inhibition induced PDK4-AMPK axis regulates metabolic adaptation and survival responses in glioma.
    Dixit D; Ahmad F; Ghildiyal R; Joshi SD; Sen E
    Exp Cell Res; 2016 May; 344(1):132-142. PubMed ID: 27001465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein kinase CK2 is important for the function of glioblastoma brain tumor initiating cells.
    Rowse AL; Gibson SA; Meares GP; Rajbhandari R; Nozell SE; Dees KJ; Hjelmeland AB; McFarland BC; Benveniste EN
    J Neurooncol; 2017 Apr; 132(2):219-229. PubMed ID: 28181105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.